A combination of PFKFB inhibitors and ER-targeted therapies block tumorsphere formation in several models of advanced breast cancer, such as tamoxifen (TamR)- and paclitaxel (TaxR)-resistant cell models, ER+ patient-derived organoids (PDxO) and murine tumor cells (46). The gene discussed is ESR1; the disease is breast cancer.